Development of a novel class of therapeutics for PTSD treatment and other neurodegenerative disorders

Project Information

FENM4PTSD

Grant agreement ID: 101144958

DOI 10.3030/101144958

EC signature date 8 December 2023

Start date 1 May 2024

End date 30 April 2026

Funded under

• The European Innovation Council (EIC)

Total cost € 3 558 661,25

EU contribution € 2 491 062,88

Coordinated by

REST THERAPEUTICS
France

CORDIS provides links to public deliverables and publications of HORIZON projects.

Links to deliverables and publications from FP7 projects, as well as links to some specific result types such as dataset and software, are dynamically retrieved from OpenAIRE .

Deliverables

Websites, patent fillings, videos etc. (1)

Website

Intermediate deliverable of task 1.3. Website content + social network newsflow/ first clinical results Second deliverable final.:Report on communication activities. Description: report gathering scientific (publications, posters, articles) and business (press release, flyers, website) communications

Publications

Peer reviewed articles (2)

Neuroprotection by chronic administration of Fluoroethylnormemantine (FENM) in mouse models of Alzheimer's disease

Author(s): Allison Carles, Aline Freyssin, Sarra Guehairia, Thomas Reguero, Michel Vignes, Hélène Hirbec, Gilles Rubinstenn, Tangui Maurice
Published in: Alzheimer's Research & Therapy, Issue 17, 2025, ISSN 1758-9193
Publisher: Springer Science and Business Media LLC
DOI: 10.1186/S13195-024-01648-9

Long-Term Treatment with Fluoroethylnormemantine (FENM) Alleviated Memory Deficits, Amyloid Pathology, and Microglial Reaction in APP/PS1 Mice

Author(s): Aline Freyssin, Allison Carles, Barbara Moha, Gilles Rubinstenn, Tangui Maurice
Published in: ACS Pharmacology & Translational Science, Issue 7, 2024, ISSN 2575-9108
Publisher: American Chemical Society (ACS)
DOI: 10.1021/ACSPTSCI.4C00522